Management of Chronic Lymphatic Leukemia Beyond conventional therapy
|
|
- Jordan Green
- 5 years ago
- Views:
Transcription
1 3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology Cytecare Cancer Hospitals Bengaluru,
2 Chronic Lymphocytic Leukemia The most prevalent type of adult leukemia Defined by CD5+, CD19+, CD2+dim, CD23, sig (dim)+ cells in blood; Monoclonal B-cell lymphocytosis (< 5 x 1 9 /l cells) Median age of diagnosis of CLL is ~ 72 yrs, (1% younger than 5 yrs of age) More common in men than women (2:1 ratio) Genetic predisposition (~ 1% of first-generation relative with CLL) Chromosomal translocations and genetic aberrations are seen in less than 3%
3 CLL - Reduces patients life expectancy For patients diagnosed with CLL before the age of 5 years, the median expected life span is only 12.3 years compared with 31.2 years in age-matched control. ADAPTED FROM SHANAFELT T, ET AL. CANCER 21;116:
4 Consideration in Management of CLL Does the patient require therapy. What would be prognostic / predictive Should you do additional testing for prognostic /predictive markers? when should treatment start? Is watch and worry still appropriate for many patients? what is your goal of therapy? what type of therapy do we choose? Intensive or non intensive The one that will give us a low MRD status. Regimen will give the best pfs/ttnt How to best manage relapse and sustain a response?
5 Despite this impact of CLL on life expectancy we still have a good measure of patients who are kept under observation. Whom do we choose to treat and not to treat? When do you choose to treat?
6 CLINICAL STAGE AND OUTCOME OF CLL Rai Stage Clinical Features Cases, % Low risk Lymphocyte count > 5 x 1 9 /L Survival, Yrs 3 > 1 Intermediate risk High risk Enlarged LN or organomegaly Hemoglobin < 11 g/dl Platelets < 1 x 1 9 /L Rai KR, et al. Blood. 1975;46:
7 Modified Indications For Treatment of Chronic Lymphatic Leukemia
8 Patients with CLL can be stratified into three subgroups according to age and comorbidities 1,2 1. Balducci L, Exterman M. Oncologist 2;5: Eichhorst B, Et Al. Leuk Lymphoma 29;5: Shanafelt T. Hematology Am Soc Hematol Educ Program 213;213:
9 The tight link between efficacy and toxicity with historical CLL therapy. Shanafelt T. Hematology Am Soc Hematol Educ Program 213;213:
10 Prognostic and predictive markers in CLL
11 CLL outcome from diagnosis: Interphase Chromosomal (FISH) Abnormalities Abnormality Pts, % Median Time to Treatment, Mos Median OS, Mos del(17)(p13.1) del(11)(q22.3) Trisomy del(13)(q14) None detected Döhner H, et al. N Engl J Med. 2;343:
12 Patients Surviving (%) CLL: Prognostic Value Of FISH FISH Abnormalities Present in 268/325 Patients (82%) Lesion % Median OS, Mos Del(13q) Del(11q) Trisomy Del(17p) 7 32 Del(6q) 6 N/A Normal FISH Lesion Dohner et al 1997 Patients with Abnormality (%) Oscier et al 1999 Jarosova et al 21 Dewald et al 23 Sindelarava et al 25 del(13q) Trisomy del(17p) del(11q) Probability of OS From Diagnosis, by Genetic Aberration 17p deletion 11q deletion 12q trisomy Normal 13q deletion as sole abnormality Dohner H, et al. N Engl J Med. 2;343: Dohner H, et al. Leukemia. 1997;11(suppl 2):S Oscier DG. Haematologica. 1999;84(suppl EHA-4): Jarosova M, et al. Onkologie. 21;24:6-65. Dewald GW, et al. Br J Haematol. 23;121: Sindelárová L, et al, Cancer Genet Cytogenet. 25;16: Mos
13 CLL: Incidence Of Genetic Lesions Incidence of Genetic Lesion, % Treatment naïve CLL [1] (n = 452) CLL8 [2] Frontline FC vs FCR (n = 635) CLL3X [3,4] High-Risk AlloSCT (n = 8) CLL2H [5,6] F-Refractory Alemtuzumab (n = 97) TP53 mut NOTCH1 mut SF3B1 mut IGHV UM del(17p) del(11q) Puente XS, et al. Nature. 215;526: Stilgenbauer S, et al. Blood. 214;123: Dreger P, et al. ASH 212. Abstract Dreger P, et al. Blood. 213;121: Schnaiter A, et al. Blood. 213;122: Schneiter A, et al. ASH 212. Abstract 71.
14 % Surviving % Treatment Free % Surviving % Surviving IGHV Mutation and Prognosis in CLL 1 Degree Of Mutation Is Related To Prognosis [1] Mutation Threshold Of 98% Was Arbitrary N = 31 Patients 5 Analyzed For Survival By Degree Of Sequence Homology For IGHV Genes OS < 97% % % 1% Homology, % Median OS, Mos < 97 NR 1 5 Treatment Free < 97% % V H 3-21 Is A Special Case [2] CLL With Rearrangement Of V H 3-21 Has A Poor Prognosis Without Regard To The Mutation Status % 2 1% Yrs 1. Hamblin TJ, et al. Brit J Haematol. 28;14: Thorselius M, et al. Blood. 26;17: Ig-unmutated V H 3-21 Ig-mutated V H Yrs Homologous V H 3-21 HCDR3 (-1 deviation) Nonhomologous V H 3-21 HCDR3
15 TP53, NOTCH1, AND SF3B1 mutations on outcome in CLL PFS TP53 AND SF3B1 MUTATIONS ASSOCIATED WITH INFERIOR PFS AND OS NOTCH1 MUTATION PREDICTED FOR DIMINISHED BENEFIT FROM RITUXIMAB OS Stilgenbauer S, et al. Blood. 214;123: Slide credit: clinicaloptions.com
16 Cumulative Proportion Progressing Cumulative Proportion Progressing NOTCH1 mutations- Lack of benefit to Anti-cd2 Mab 123 CLL symptomatic patients homogeneously treated with first-line fludarabine followed by consolidation rituximab in responding patients NOTCH1 mut -Significant associations with trisomy 12 (p =.3) and unmutated IGHV (p =.1)2 of 123 pts (16.3%). ASSOCIATED WITH INFERIOR RESPONSE RATES, PFS Response Duration by NOTCH1 Mutations P =.4 n = 13 NOTCH1 wild type NOTCH1 mutated Response Duration by Unconsolidated vs NOTCH1 wt and NOTCH1 Mut Consolidated Pts n = 1 n = 49 Unconsolidated Consolidated NOTCH1 wt Consolidated NOTCH1 mut.4.2 n = n = 21 P =.7 P = Mos From the End of Induction Therapy Mos From the End of Induction Therapy Del Poeta G, et al. 213 EHA. Abstract P12
17 So where is this knowledge taking us with regards to management of CLL? Outcomes with CT/ CIT treatment for CLL?
18 Cumulative Survival CLL8 : PFS Survival Functions FC FCR FC censored FCR censored N = 817 Median PFS, Mos FC: 32.9 FCR: HR:.56 (95% CI: ; P <.1) Mos Fink A, et al. ASH 211. Abstract 977.
19 OS CLL8 TRIAL: FIRST-LINE FC VS FCR FCR (n = 48) Median follow-up: 7 mos HR:.7; P =.1 FC (n = 49) Fischer K, et al. ASH 212. Abstract 435. Mos
20 Cumulative Survival CLL1: PFS (PRIMARY ENDPOINT) AND OS WITH FCR VS BR IN PTS WITH ADVANCED CLL 1..8 PFS Median PFS, Mos FCR 55.2 BR OS.6.6 P = P <.1 HR: (> non-inferiority cut-off) Mos 6.2 OS at 36 Mos, % FCR 9.6 BR Mos to Event (OS) 6 Eichhorst B, et al. ASH 214. Abstract 19.
21 Does CIT produce long term responses?
22 Pts (%) Pts Progression Free (%) FCR3 Phase II Trial: Plateau in PFS with FCR As Initial Therapy For CLL WITH EXTENDED FOLLOW-UP, PFS 1 75 SHOWS PLATEAU AT YRS 1-11 N Event Free OS PFS 3 11 LAST RELAPSES OCCURRED AROUND YR 1, WITH A PLATEAU IN PFS FOR IGHV-MUTATED PTS 1 75 N IGHV mutated IGHV unmutated Progression Free Yrs P < Yrs Thompson PA, et al. Blood. 215 Oct 22.
23 Does the newer Anti CD2 mabb have an advantage?
24 Probability of PFS Probability of OS Probability of PFS Probability of OS CLL11: Survival with Clb/Obinutuzumab Vs Clb Alone or Clb/Rituximab in CLL O-Clb 26.7 Clb HR:.18 (95% CI: ; P <.1) HR:.39 (95% CI: ; P <.1).4 O-Clb.2 R-Clb Mos Goede V, et al. N Engl J Med. 214;37: HR:.41 (95% CI: ; P <.2).4.2 O-Clb Clb HR:.66 (95% CI: ; P =.8) O-Clb R-Clb Mos
25 CLL11: Response with CLB/Obinutuzumab Vs CLB alone or CLB/Rituximab in CLL Response, % O-Clb (n = 238) Clb (n = 118) R-Clb (n = 233) ORR CR PR Pts With MRD-Negative Test, % O-Clb R-Clb P Value Bone marrow <.1 Blood <.1 Goede V, et al. N Engl J Med. 214;37:
26 Targeting specific pathways A paradigm change in the management of CLL
27 Critical signaling pathways and new targeted agents In B-cell Malignancies BCR BCR signaling is required for tumor expansion and proliferation BCR signaling up-regulated Ibrutinib BTK LYN SYK PI3K delta Idelalisib Duvelisib Pilaralisib in CLL New inhibitors targeting multiple components of BCR PKC PLCγ2 Everolimus GSK-3 AKT mtor NF-kβ pathway signaling including pi3k delta, BTK, and SYK p7s6k elf4e
28 Targeting Bruton Kinase Ibrutinib in CLL
29 Pts (%) Pts With Response (%) PHASE II (PCYC-112/PCYC-113) IBRUTINIB MONOTHERAPY TRIAL IN CLL/SLL 1 PTS WITH CLL/SLL: TX NAIVE (N = 31) AND R/R WITH PD < 24 MOS AFTER CHEMOIMMUNOTHERAPY OR FAILURE TO RESPOND (N = 11) PTS RECEIVED IBRUTINIB 42 OR 84 MG/DAY PO ORR: 84% Untreated 65 Yrs of Age (n = 31) Best response to ibrutinib improves over time ORR: 9% R/R (n = 11) ORR: 8% 6 R/R del(17p) (n = 34) ORR: 89% Byrd JC, et al. Blood. 215;125: Total (N = 132) CR PR PR-L SD PD CR PR PR-L Mos From Initiation of Study Treatment 4
30 Proportion Achieving PFS Proportion Achieving OS Ibrutinib Monotherapy 3 Yrs Postinitiation In CLL/SLL: PFS, OS By Cytogenetics PFS OS del(17p) del(11q) No del(17p) or del(11q).4.2 del(17p) del(11q) No del(17p) or del(11q) Log-rank P =.31 Log-rank P = Mos From Initiation of Study Treatment Mos From Initiation of Study Treatment del(17p) R/R (n = 34) del(11p) R/R (n = 28) No del(17p/11q) R/R (n = 34) del(17p) R/R (n = 34) del(11p) R/R (n = 28) No del(17p/11q) R/R (n = 34) 3-mo PFS, % (95% CI) 48 (29-65) 74 (53-87) 87 (68-95) 3-mo OS, % (95% CI) 65 (46-79) 85 (65-94) 9 (73-97) Median PFS, mos (95% CI) 28 (18.2-NE) 38.7 (31.2-NE) NR (NE-NE) Median OS, mos (95% CI) NR (21.5-NE) NR (41.4-NE) NR (NE-NE) Byrd JC, et al. Blood. 215;125:
31 RESONATE-2: Ibrutinib Vs Chlorambucil In Pts 65 Yrs Of Age With Tx-naive CLL/SLL AN INTERNATIONAL, RANDOMIZED PHASE III TRIAL Pts 65 yrs of age or older with treatmentnaive CLL/SLL; no warfarin use; no del(17p) (N = 269) Ibrutinib 42 mg/day until progression Chlorambucil.5 mg/kg (up to maximum of.8 mg/kg) on Days 1, 15 of 28-day cycle for up to 12 cycles Crossover upon PD (n = 43) Burger JA, et al. N Engl J Med PRIMARY ENDPOINT: PFS SECONDARY ENDPOINTS: OS, ORR, EFS, RATE OF HEMATOLOGIC IMPROVEMENT, AND SAFETY
32 Pts With PFS (%) Pts Who Survived (%) RESONATE-2: Superior Efficacy With Ibrutinib Vs Chlorambucil For Elderly Pts 1 PFS Ibrutinib 1 OS Ibrutinib 8 8 Chlorambucil 6 Chlorambucil Median, mos Clb 18.9 Ibrutinib NR HR:.16 (95% CI:.9-.28; P <.1) Mos AEs Summary Ibrutinib Chlorambucil Most frequent AEs Burger JA, et al. N Engl J Med. 215; Diarrhea, fatigue, cough and nausea Nausea, fatigue, neutropenia, anemia, and vomiting AEs leading to discontinuation, % HR:.16 (95% CI:.5-.56; P <.1 by log-rank test) Mos
33 Phase III RESONATE: Ibrutinib Vs Ofatumumab In Previously Treated CLL/SLL CLL/SLL diagnosis 1 prior therapy ECOG PS -1 Measurable nodal disease by CT Ibrutinib 42 mg/day PO until PD or unacceptable toxicity (n = 195) Ofatumumab IV starting dose of 3 mg followed by 2 mg x 11 doses for 24 wks (n = 196) Crossover = 122 pts To Ibrutinib 42 mg/day following PD Primary goal: updated efficacy results, with median treatment duration of 16 mos, relative to genetic features and prior treatment exposure, and updated AE data Brown JR, et al. ASH 214. Abstract Byrd JC, et al. N Engl J Med. 214;371:
34 PFS (%) RESONATE: Ibrutinib Vs Ofatumumab In Previously Treated CLL/SLL HR:.215 (95% CI: ) 4 2 RICHTER S TRANSFORMATION CONFIRMED IN 2 PTS ON EACH ARM; Byrd JC, et al. N Engl J Med. 214;371: Log-rank P <.1 Ibrutinib Ofatumumab Median PFS, mos NR Mos 1 ADDITIONAL PT ON IBRUTINIB EXPERIENCED DISEASE TRANSFORMATION TO PROLYMPHOCYTIC LEUKEMIA
35 PFS (%) 1 RESONATE: PFS By Del(17p) With Ibrutinib Vs Ofatumumab In CLL/SLL 8 Ibrutinib del(17p) ibrutinib no del(17p) Ofatumumab del(17p) Ofatumumab no del(17p) Median PFS, mos NR NR HR: (95% CI: ; P =.396) HR: (95% CI: ; P =.39) Mos For ibrutinib, no significant difference in PFS with or without del(17p) Brown JR, et al. ASH 214. Abstract 3331.
36 Cumulative Incidence of Discontinuation of Ibrutinib Therapy (%) Retrospective Study: Time To Discontinuation of Ibrutinib SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF 38 PTS PARTICIPATING IN 4 SEQUENTIAL TRIALS OF IBRUTINIB Cumulative Incidence, % (95% CI) 12 Mos 18 Mos Other event 13.5 ( ) 15.6 ( ) Richter s transformation 4.5 (2.-7.) 6.5 ( ) CLL progression.3 (-1.) 2.4 (.3-4.6) Mos Maddocks KJ, et al. JAMA Oncol. 215;1:
37 PFS (%) OS (%) PFS (%) PFS (%) Ibrutinib vs Ofatumumab (Phase III RESONATE) [1] Single-agent Ibrutinib (5-year follow up from phase Ib/II study) [2] TP53 Status Affects Survival In Relapsed/Refractory CLL Treated With Ibrutinib Ibrutinib with del(17p) (n = 63) Ibrutinib without del(17p) (n = 132) Ofatumumab with del(17p) (n = 64) Ofatumumab without del(17p) (n = 132) Mos del(17p) del(11q) Trisomy 12 del(13q) No abnormality Ibrutinib without or with del17p HR: (95% CI: ) Log-rank P = Brown JR, et al. Leukemia. 218;32: O Brien S, et al. Blood. 218;131: Mos From Initiation of Study Treatment Log-rank P.1737 comparing del(17p) and TP53 vs del(17p) or TP53 mutation Log-rank P.381 comparing del(17p) and TP53 vs no del(17p) or TP53 mutation Log-rank P.522 comparing del(17p) or TP53 mutation vs no del 17p or TP53 mutation Mos No del(17p) or TP53 mutation (n = 68) del(17p) or TP53 mutation (n = 48) del(17p) and TP53 mutation (n = 38) del (17p) del (11q) Trisomy 12 del (13q) No Abnormality Mos From Initiation of Study Treatment
38 IBRUTINIB: CONCLUSIONS Ibrutinib is very active in pts with Treatment naïve and R/R CLL produces ORR of 8% to 9%, with CR of 6% to 7%, and 53% of pts remain on ibrutinib at median 3-yr follow-up No significant difference in pfs, regardless of del(17p) status Ibrutinib can result in various AEs Rate of atrial fibrillation is less than 1% Increases bleeding risk, but most bleeding is mild and not serious Use caution when combining with anticoagulants or in pts with predisposing risk factors Slide credit: clinicaloptions.com
39 PI3K Signaling Pathway As A Target In B Cells BCR LYN SYK p85 p11 PI3K Delta AKT PTEN P PIP 2 P P Proliferation Cyclin-D p27 kip1 GSK-3ß Bad Cell survival FoxO mtor IKK ASK Protein synthesis NF-kB pathway SAPK/JNK pathway
40 PFS (%) OS (%) Screen Arm A n = 11 Arm B n = 11 Randomization/ Stratification Idelalisib, A Pi3kd Inhibitor, Overcomes Adverse Effect Of TP53 Aberration Population: Relapsed CLL warranting treatment (iwcll); progression < 24 mos since last treatment Primary Study 116 Extension Study 117 Double-Blind Initial Therapy Rituximab (6 mos) Rituximab (6 mos) Double- Blind Continuous Therapy Idelalisib (15 mg BID) Placebo (BID) Blinded, Independent Review Sharman JP, et al. ASH 214. Abstract 33. Disease Progression Blinded Dose Open Label Idelalisib (3 mg BID) Idelalisib (3 mg BID) Interim Analyses and Unblinding Independent Review PFS in TP53-Aberrant Patients With Idelalisib + Rituximab No del del del(17p)/tp53mut: Present vs Not Present 2 No del(17p)/tp53mut (n = 64) Del(17p)/TP53mut (n = 46) Mos Median PFS (95% CI) No del 2.3 mos (19.4, - ) del 16.6 mos (13.9, - ) P Value.94 OS in TP53-Aberrant Patients With Idelalisib + Rituximab vs Control IDELA + R PBO + R del(17p)/tp53mut: Mutation (Either) 2 Idelalisib + R (n = 46) Placebo + R (n = 49) Mos Median OS (95% CI) IDELA + R NR (18.8,- ) PBO + R 14.8 mos (8.4, - ) HR (95% CI) ( ) 1 P Value.1
41 IDELALISIB: TOXICITIES Diarrhea: occurs in 2 forms Self-limiting: usually mild; early onset (median 1.5 mos); responds to common antidiarrheal agents Severe diarrhea: late onset (median 7 mos); responds poorly to antimotility agents but appears to be responsive to budesonide and/or systemic corticosteroids Transaminase elevations: generally reversible Usually occurs within first 12 wks 74% of pts with treatment interruption able to resume idelalisib at a lower dose without recurrence Permanently discontinue idelalisib if ALT/AST > 2 x ULN Pneumonitis: consistent with reports with mtor inhibitors Any pt who presents with pulmonary symptoms should be evaluated for pneumonitis Hold idelalisib with any symptomatic pneumonitis Often treated with corticosteroids in addition to continuing antibiotics and holding idelalisib if no improvement Coutre SE, et al. Leuk Lymphoma. 215;56:
42 Targeting the BCL2 receptor. Venetoclax the new star for CLL management
43 Targeting BCL 2 Venetoclax: Mechanism Of Action 1 Proapoptotic proteins (BAX, BAK) An Increase in BCL-2 Expression Allows the Cancer Cell to Survive Antiapoptotic proteins (BCL-2) 2 Venetoclax Binds to and Inhibits Overexpressed BCL-2 BH3-only Venetoclax 3 Apoptosis is Initiated Active caspase Apoptosome APAF-1 Cytochrome C Procaspase BAK BAX BCL-2 BCL-2 Mitochondria Mitochondria Mitochondria Kumar S, et al. ASCO 215. Abstract 8576.
44 Venetoclax + Rituximab In R/R CLL: Phase Ib Dose-escalation Strategy Wk 1 Wk 1 Wk 2 Wk 3 Wk 4 Mo 1 Mos 2-6 Day 1 Days mg 5 mg 1 Cohort Cohort Cohort 2 mg mg Dose Dose Dose Mo 7 and ongoing Venetoclax monotherapy Rituximab: Day 1 Day 1 of Mos mg/m 2 5 mg/m 2 Protocol-defined option to stop venetoclax after achieving CR or MRD-negative PR Dose-escalation phase: 2, 3, 4, 5, 6-mg/day cohorts (n = 41) Safety expansion phase: 4-mg/day cohort (n = 8) Data pooled for safety and efficacy analyses Seymour JF, et al. Lancet Oncol. 217;18:23-24.
45 Venetoclax + Rituximab In R/R CLL: Outcomes After Discontinuing Therapy MRD-positive CR/CRi MRD-negative CR/CRi MRD-negative PR Seymour JF, et al. Lancet Oncol. 217;18: * * Time on venetoclax Time off venetoclax Asymptomatic progression Best iwcll and MRD response Discontinued from study Lost to follow-up Mos *
46 Venetoclax Monotherapy: Phase II Trial In Ultrahigh-risk R/R CLL With Del(17p) PFS and OS (N=17) Week 1* D1 Week 1 D2 7 Week 2 Week 3 Week 4 and following Venetoclax 2 mg test 5 mg 1 mg 2 mg 4 mg Objectives: Primary: ORR by IRC assessment Secondary: CR/PR rates, time to first response, DoR, PFS, OS, safety Exploratory: MRD (flow cytometry, sensitivity <1-4 ) Key Inclusion: Rel/ref CLL, del(17p) confirmed by central laboratory ECOG score 2 ANC 1K/µL; Plt 4K/µL; Hgb 8 g/dl Creatinine clearance 5 ml/min Key Exclusion: AlloBMT, Richter s, uncontrolled autoimmune cytopenia, other malignancy, major organ dysfuction Risk-based tumor lysis monitoring Weekly step-wise weekly ramp-up Response assessment (iwcll 28): CBC, PE monthly CT scan to confirm clinical response (prespecified at week 36) Bone marrow biopsy to confirm CR 12-MO OS: 86.7% (95% CI: 78.6% TO 91.9%) Stilgenbauer S, et al. ASH 215. Abstract LBA-6. Stilgenbauer S, et al. Lancet Oncol. 216;17: MO PFS: 72% (95% CI: 61.8% TO 79.8%)
47 MURANO Interim Analysis: Study Design MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE III TRIAL Stratified by del(17p), prior tx response*, geographic region 28-day cycles Adult patients with R/R CLL, 1-3 prior tx lines (with 1 CTcontaining regimen), prior bendamustine permitted if DoR 24 mos (N = 389) Venetoclax dose ramp-up 2-4 mg PO QD for 5 wks then 4 mg PO QD for C1-6 + Rituximab 375 mg/m 2 on Day 1 of C1, then 5 mg/m 2 Day 1 of C2-6 (n = 194) Bendamustine 7 mg/m 2 on Days 1, 2 of C1-6 + Rituximab 375 mg/m 2 on Day 1 of C1, then 5 mg/m 2 Day 1 of C2-6 (n = 195) Venetoclax monotherapy until PD, unacceptable toxicity, or maximum of 2 yrs from Day 1 of C1 *High-risk CLL defined as: del(17p); no response to first-line CT-containing tx; or relapsed in 12 mos after CT or in 24 mos after chemoimmunotherapy. Primary endpoint: investigator-assessed PFS Secondary endpoints: IRC-assessed PFS and MRD negativity, IRC-assessed CR ORR OS (hierarchical testing), safety Seymour JF, et al. ASH 217. Abstract LBA-2. ClinicalTrials.gov. NCT25471.
48 PFS (%) MURANO Interim Analysis: Investigator-assessed PFS Pts at Risk, n VEN + R BR HR:.17 (95% CI: ); P <.1 Pts, n mpfs, Mos 1-yr PFS, % 2-yr PFS, % VEN + R 194 NR BR Censored Mos MEDIAN F/U: 23.8 MOS (-37.4) COMPLETED 2-YRS WITHOUT PROGRESSION, N = 65; PTS WITH 3-MO F/U, N = 12 IRC-ASSESSED PFS CONCORDANT WITH INVESTIGATOR ASSESSMENT MPFS FOR VEN + R VS BR: NR VS 18.1 MOS (HR:.19; 95% CI: ; P <.1) Seymour JF, et al. ASH 217. Abstract LBA-2. Reprinted with permission.
49 PFS (%) MURANO Interim Analysis: Investigator-assessed PFS By Del(17p) Status Pts at Risk, n VEN + R with del(17p) VEN + R without del(17p) BR with del(17p) BR without del(17p) HR for VEN + R vs BR (95% CI) With del(17p).13 (.5-.29) Without del(17p).19 ( ) VEN + R with del(17p) (n = 46) VEN + R without del(17p) (n = 127) BR with del(17p) (n = 46) BR without del(17p) (n = 123) Censored Mos Venetoclax + rituximab consistently favored across subgroups stratified by del(17p) status, TP53 status, baseline IGHV status, no. prior tx, refractory vs relapse to last tx Seymour JF, et al. ASH 217. Abstract LBA-2. Reprinted with permission.
50 Pts (%) Pts (%) MURANO Interim Analysis: MRD Negativity Higher rates of blood MRD negativity achieved and maintained with VEN + R vs BR MRD Negativity,* (n) % VEN + R (n = 194) Seymour JF, et al. ASH 217. Abstract LBA-2. BR (n = 195) BL 4 mos 88 (45) 11 (6) 9 mos 121 (62) 26 (13) 12 mos 117 (6) 2 (1) 15 mos 11 (57) 19 (9) 18 mos 116 (6) 1 (5) *MRD negative: < 1 CLL cell/1, leukocytes (1-4 ). Centrally assessed every 3 mos after end of combination therapy or at response by multicolor flow cytometry and/or ASO-PCR; only 1 positive assay needed to report as MRD positive. ITT analysis with missing MRD data or failed assay reported as MRD positive. End of combination therapy VEN + R (n = 194) Mos BR (n = 195) Mos MRD negative MRD positive Assay failure PD/death/withdrew Sample missing
51 Venetoclax + Ibrutinib In CLL: Study Design Investigator-initiated, single-arm, multicohort phase ii (n=116) Adult pts with CLL/SLL meeting IWCLL 28 criteria with either R/R disease (cohort 1, n = 37) or untreated high-risk* disease (cohort 2, n = 4), adequate organ function, no prior IBR, no prior VEN Ibrutinib 42 mg QD in 28-d cycles Primary endpoint: CR/CRi per IWCLL 28 criteria Jain N, et al. ASH 217. Abstract 429. ClinicalTrials.gov. NCT Cycle 3 Ibrutinib 42 mg QD + Venetoclax dose escalation to 4 mg QD Other endpoints: OS, TLS risk categorization at BL vs post-ibr, safety IBR: until PD VEN: for 2 yrs * 1 of following high-risk characteristics: 65 yrs of age; del(11q); del(17p) or mutated TP53; unmutated IGHV. Venetoclax weekly dose escalation (all doses QD): 2 mg, 5 mg, 1 mg, 2 mg, 4 mg. Response assessment by blood, BM, CT every 3 mos during Yr 1, every 6 mos during Yr 2, then every 6-12 mos thereafter.
52 Pts (%) Venetoclax + Ibrutinib In CLL: Response In R/R Disease (Cohort 1) CR/CRi PR (any LN > 1.5 cm by CT) BM MRD negative (by 4-color flow cytometry; sensitivity 1-4 ) Mo IBR (n = 34) 8 3 Mo VEN + IBR (n = 26) 31 6 Mo VEN + IBR (n = 16) Mo VEN + IBR (n = 13) Mo VEN + IBR (n = 5) Jain N, et al. ASH 217. Abstract 429. Reprinted with permission.
53 Pts (%) Venetoclax + Ibrutinib In CLL: Response In Untreated High-risk Disease (Cohort 2) CR/CRi PR (any LN > 1.5 cm by CT) BM MRD negative (by 4-color flow cytometry; sensitivity 1-4 ) Mo IBR (n = 36) Mo VEN + IBR (n = 33) Mo VEN + IBR (n = 2) 2 9 Mo VEN + IBR (n = 1) 12 Mo VEN + IBR (n = 3) Jain N, et al. ASH 217. Abstract 429. Reprinted with permission.
54 How can we look at approaching a CLL patient requiring treatment today?
55 Population Initial Therapy Relapsed Therapy Younger, fit pts with low risk Older pts with comorbidities Pts with del(17p) or TP53 mutation *Not currently approved by the FDA. FCR (especially mutated IGHV) Bendamustine/rituximab Chlorambucil/obinutuzumab Chlorambucil/ofatumumab Ibrutinib Ibrutinib AlloSCT? Ibrutinib Idelalisib + R Ibrutinib + BR* Idelalisib + BR* Venetoclax* Ibrutinib Idelalisib + R Venetoclax Ibrutinib Idelalisib + R AlloSCT?
56
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker
More informationPost-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford
Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationUPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Apply recent clinical research findings with the newly FDA-approved combination of obinutuzumab and chlorambucil to the management and care of patients with previously
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationDebate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationDefining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia
Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationIndustry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia
Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia Davy Chiodin with Nadia Ono Regulatory Science Acerta (A Member of the AstraZeneca Group) 09 November 2018 1
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY 3
The Bruton s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationEfficacy of Bendamustine and rituximab in a real-world patient population
Efficacy of Bendamustine and rituximab in a real-world patient population Median follow-up 37,1 months Efficacy of bendamustine and rituximab as first salvage treatment in CLL and indirect comparison with
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationCLL: State of the Art 2018
CLL: State of the Art 2018 Dr. Susan O Brien, MD Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials
More informationWhat s on the Horizon for Chronic Lymphocytic Leukemia?
What s on the Horizon for Chronic Lymphocytic Leukemia? Matthew S. Davids, MD, MMSc Associate Director Center for Chronic Lymphocytic Leukemia Assistant Professor of Medicine Harvard Medical School Dana
More informationWelcome & Introductions
Living with Chronic Lymphocytic Leukemia (CLL) Welcome & Introductions Dr. Brander s slides are available for download at www.lls.org/programs Wednesday, July 12, 2017 1 Living with Chronic Lymphocytic
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationEmerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia
Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia This educational activity is supported by an educational grant from AbbVie Faculty Jennifer R Brown, MD PhD
More informationRole of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD
Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD Department of Hematology Levine Cancer Institute Carolinas Health
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationGP CME. James Liang Consultant Haematologist. Created by: Date:
GP CME James Liang Consultant Haematologist Date: Created by: Scenario 52 year old European male Fit and well Brother recently diagnosed with diabetes PMHx Nil Social Hx Ex-smoker stopped 5 years ago (20
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationTargeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board
Targeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board Segment 1 Segment Title: Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL Segment Description: William Wierda, MD, PhD, and
More informationIdelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationWaldenström s Macroglobulinemia: Treatment Approach
Waldenström s Macroglobulinemia: Treatment Approach Steve Treon MD, PhD Bing Center for Waldenstrom s Macroglobulinemia Dana Farber Cancer Institute Harvard Medical School Primary Therapy of WM with Rituximab
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationMolecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University
Molecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University Chronic Lymphocytic Leukaemia (CLL) Most common leukaemia in adults Diagnosis straightforward CD19+/CD5+/CD23+
More informationVENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth
VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth ABT-199 Venetoclax ABT-199 is a selective, potent, orally
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More information